Canada: Developed, Welcoming Trial Territory
Pharm-Olam has been conducting clinical trials in Canada since 2003
- FDA/EMA approvals include trials in:
- Premature ejaculation
- Pharm-Olam clinicians are bilingual (English, French)
Attractive Regulatory Framework and Timelines
Fast-track your trial in a hospitable clinical study environment.
- At 30 days or less, Canada boasts one of the world’s shortest clinical trial approval timelines
- A No-Objection-Letter (NOL), issued by Health Canada upon approval of a trial, doubles as an import license
- Scientific Research & Experimental Development tax credits available
- Trials may be promoted through any media in Canada
Familiar, Yet Unexploited, Trial Market
Canada resembles the U.S. and is well-suited for recruitment.
- Six large metropolitan areas with populations of at least 1 million
- Open trials per capita is .0089 (versus .021 in the U.S.)
- Comparably unsaturated trial market relative to U.S.
- Comparable physician:patient ratio to U.S. (2.2 doctors per 1,000 residents)
Role of Clinical Trials is Established, Accepted
Sponsors will find culture, patient profile are conducive to study success.
- Long life expectancy: 81.1 years (10 years longer than global average)
- Diverse pathology profile: ischemic heart disease, bronchus, lung cancers, and cerebrovascular disease are leading causes of premature death
- Patients are generally receptive to trial participation:
- Pharmaceuticals not covered by the Canada’s universal health plan
- Patients endure longer wait times than U.S. (e.g., depending upon indication, wait times for an MRI could be several months)
- Trials are an attractive alternative to waiting for treatment via the publicly funded healthcare system